key: cord-0749736-yxaji0r8 authors: Climax, John; Hamza, Moayed; Lafferty, Adam; Guilfoyle, Kate; van Amerongen, Geert; Stadler, Konrad; Wohlsein, Peter; Baumgärtner, Wolfgang; Weissbach, Markus; Coughlan, David title: Orally administered epeleuton inhibits SARS-CoV-2 viral load, replication and pathology in the Syrian Hamster model date: 2021-12-09 journal: bioRxiv DOI: 10.1101/2021.12.07.471588 sha: bb9aa718a041cba3a4331fc74b3def98a8097cbd doc_id: 749736 cord_uid: yxaji0r8 Early treatment of patients with confirmed COVID-19 presenting mild symptoms can reduce the number that progress to more severe disease and require hospitalization. Considering the potential for the development of drug resistance to existing therapies and the emergence of new SARS-CoV-2 variants, there is a need for an expanded armamentarium of treatment options for COVID-19. Epeleuton is a novel orally administered second-generation n-3 fatty acid with potential direct antiviral and immunomodulatory actions, and a favourable clinical safety profile. In this study we show that epeleuton inhibits SARS-CoV-2 infectious viral load, replication and disease pathology in the lungs and upper airways in the Syrian hamster model of SARS-CoV-2 infection. These data support the potential utility of epeleuton in the early treatment and prevention of SARS-CoV-2 infection. Clinical trials are needed to evaluate the efficacy of epeleuton as an outpatient treatment and prevention of COVID-19. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 and follows SARS-CoV and MERS as the third highly pathogenic coronavirus in the last twenty years 1 . COVID-19 can range in severity from a mild respiratory illness to severe disease progressing to pneumonia, acute respiratory distress syndrome (ARDS), multi-organ failure, and death 2 . As of early December 2021, there have been more than 262 million confirmed cases of COVID-19 globally and more than 5.2 million deaths reported to WHO. More than 7.8 billion vaccine doses have been administered. Indeed, the availability of SARS-CoV-2 vaccines has substantially mitigated COVID-19 outbreaks and aided in the global response to the COVID-19 pandemic. COVID-19 vaccination has been effective in reducing the number of new SARS-CoV-2 infections, hospitalizations and deaths 3, 4 . However, uncertainties remain regarding the longevity of protection conferred by vaccination, and global disparities remain in the access and adoption of vaccines 5 . These factors contribute to a complex and varied epidemiology at both a global and regional level. Within this evolving context, early treatment of patients with confirmed COVID-19 presenting mild symptoms can reduce the number of patients that progress to more severe disease and require hospitalization or admission to intensive care units. However, there is a paucity of therapeutic options for COVID-19 treatment in an outpatient setting and there is an urgent need for new therapeutics. Emergency use authorisations of effective therapeutics such as REGN-COV2 6 and the emergence of molnupiravir 7 and Paxlovid 8 are important milestones but the need for an expanded armamentarium of therapeutic options and modalities is especially evident considering the potential for development of drug resistance to existing therapies 9 , the emergence of new SARS-CoV-2 variants 10 and the anticipated disparities in access to newly approved treatments. Epeleuton is 15-hydroxy eicosapentaenoic acid 15(S)-HEPE) ethyl ester, a second-generation synthetic n-3 fatty acid derivative of eicosapentaenoic acid (EPA). It is rapidly de-esterified to its active form, 15(S)-HEPE following oral administration. 15(S)-HEPE, at much lower concentrations, is an endogenous downstream 15-lipoxygenase metabolite of EPA. Epeleuton is associated with cardiometabolic and anti-inflammatory effects in clinical and preclinical studies 11 . The therapeutic effects of 15(S)-HEPE are thought to be induced by pleiotropic modes of action. As of mid-October 2021, epeleuton has completed an extensive toxicological evaluation and been administered to more than 300 subjects in phase 1 and phase 2 clinical trials, with a favourable safety and tolerability profile similar to placebo. Epeleuton is in phase 2b clinical development as a treatment for hypertriglyceridemia, type 2 diabetes and cardiovascular risk reduction (NCT04365400). There is accumulating evidence that polyunsaturated fatty acids have anti-inflammatory, immunomodulatory and anti-viral properties, which may confer beneficial effects against SARS-CoV-2 infection 12 . Lipids play important roles in viral entry and replication, interacting with viruses throughout their life cycle. Consequently, exogenous lipid mediators may regulate the host immune response to viral infection. Several potential binding targets for fatty acids have been identified including targets for fatty acid binding on the spike protein (S) and envelope protein of SARS-CoV-2 13, 14 . A recent study found that the S protein binds the free fatty acid linoleic acid (LA). LA binding stabilized a locked S conformation, resulting in reduced angiotensin-converting enzyme 2 (ACE2) interaction. A similar binding pocket was also present in the other highly pathogenic coronaviruses, SARS-CoV and MERS 13 . Building on this discovery it was reported that LA and EPA, the metabolic precursor of epeleuton's active moiety 15(S)-HEPE can interfere with binding to ACE2 and significantly block the entry of SARS-CoV-2 15 . We postulated that due to the potential of epeleuton to impact both the host immune response and to directly decrease pathogen burden by acting directly against SARS-CoV-2, epeleuton may exert a beneficial effect in the early treatment and prevention of SARS-CoV-2 infection. In this work we determined the distribution of 15(S)-HEPE in lungs and other tissues of interest and subsequently assessed the potential of orally administered epeleuton to control SARS-CoV-2 infection and improve histopathological outcomes in the Syrian hamster model. We show that epeleuton decreases viral loads, viral RNA and pathology in both the upper and lower respiratory tract. These findings support the potential of epeleuton as an orally administered drug for the early treatment and prevention of SARS-CoV-2 infection. Epeleuton (15(S)-HEPE EE) is rapidly de-esterified to its active moiety, 15(S)-HEPE following oral administration. 15(S)-HEPE is expected to exhibit similar distribution as generally known for fatty acids absorbed orally -solubilised as chylomicrons, distributed to various tissues, and released as free fatty acids through the action of tissue lipoprotein lipases 16 . Herein, we sought to investigate the tissue distribution pattern of orally administered 15(S)-HEPE EE or vehicle in Sprague Dawley rats (n=5/group) following a QDx7 dosing schedule. Post-mortem tissue analysis (Day 8) revealed significant increases in the concentrations of 15(S)-HEPE in the tissues of treated animals compared to vehicle control ( Figure 1 ). The mean concentrations of absorbed 15(S)-HEPE in various tissues 24 hours after the last administration of Epeleuton are as follows; Lung (6742 ng/g), heart (272 ng/g), liver (610 ng/g), kidneys (923 ng/g), skin (299 ng/g), eyes (200.96 ng/g) and spleen (1975 ng/g). On Day 8, 24 hours after the last administration, 15(S)-HEPE concentrations were below the limit of detection in the plasma and brain of treated rats in line with the plasma pharmacokinetics of the compound. While increases in 15(S)-HEPE concentrations were significant across all organs, the greatest concentrations compared to control were detected in the lungs (0ng/g vehicle control vs 6742ng/g 500mg/kg Epeleuton, P = < 0.05, Fig 1) . Mean concentration is presented for each organ. Error bars represent standard deviation (S.D). Asterisk represents statistical significance versus vehicle control; * p=.033, ** p=.002. Due to an inherent susceptibility to SARS-CoV-2 infection, Syrian hamsters are a commonly Epeleuton dose selection was based on human equivalent doses 18 corresponding to a 2g/day and 4g/day clinical dose, a well-tolerated clinical dosing regimen for epeleuton employed in ongoing clinical trials. All animals were administered vehicle or epeleuton (250mg/kg or 500mg/kg) once daily for 5 days prior to challenge with SARS-CoV-2. To investigate the antiviral effects of epeleuton, nine-to ten-week-old male hamsters (n=18) were inoculated intranasally with a dose of 1x10 2 TCID50 SARS-CoV-2. Treatment continued for 3 days. All animals were sacrificed on day 4 p.c. for tissue collection. Viral shedding was determined from daily throat swabs. The lower limit of quantification was determined to be 0.8 Log10 TCID50/ml, and represents undetectable viral titers. In the vehicle control arm, viral titers of 2.7 Log10 TCID50/ml were detected at day 1 (n=6). Peak viral shedding was detected on day 2 (3.6 Log10 TCID50/ml) with subsequent decreases in viral titer at days 3 and 4 (2.8 Log10 TCID50/ml and 1.8 Log10 TCID50/ml respectively, Fig. 2c ). Epeleuton, when administered at a 250mg/kg dose, decreased viral shedding on days 1 and 2 characterised by significant (p = < 0.05) reductions in viral titer of 1.6 Log10 TCID50/ml and 1.9 Log10 TCID50/ml respectively. An improved effect on viral shedding was observed in animals that received 500mg/kg epeleuton. Significant decreases in viral shedding were observed up to 3 days p.c.. At both days 1 and 2, viral titers were undetectable (0.8 Log10 TCID50/ml) in animals treated with 500mg/kg Epeleuton. A significant reduction (p = < 0.05) of 1.2 Log10 TCID50/ml was observed on day 3. Viral replication and infectious titers in the lungs and nasal turbinates were determined from tissue samples on day 4, the peak of viral load and replication. Epeleuton decreased lung viral titers in a dose-dependent manner. A mean titer of 8.0 Log10 TCID50/g was detected in the lungs of vehicle control hamsters on day 4 (Fig. 2d) . Treatment with 250mg/kg epeleuton reduced viral titers in the lungs by 1.3 Log10 TCID50/g (non-significant). Epeleuton when administered at a higher dose produced a significantly improved effect reducing infectious titers in the lungs by 3.1 Log10 TCID50/g. Epeleuton produced a similar non-significant trend in nasal turbinates. Treatment with 250mg/kg and 500mg/kg epeleuton reduced viral titers in the nasal turbinates by 1.1 Log10 TCID50/g and 1.7 Log10 TCID50/g respectively (Fig. 2E ). As a secondary measure of viral shedding, viral RNA genome copy number was quantified in daily throat swabs, nasal turbinates and lung tissue. The lower limit of quantification was determined to be 1.9 Log10 copies/ml/g, and represents undetectable viral RNA. In the vehicle control arm, viral RNA of 5.6 Log10 copies/ml were detected at day 1 (n=6). Peak viral RNA was detected on day 2 (6.8 Log10 copies/ml) with subsequent decreases in viral RNA at days 3 and 4 (5.9 Log10 copies/ml and 5.3 Log10 copies/ml respectively, Fig. 2F ). Epeleuton administered at doses of 250mg/kg and 500mg/kg resulted in significant dose dependent reductions (p = < 0.05) in viral RNA up to 3 days p.c (500mg/kg). Epeleuton, when administered at a 250mg/kg dose, exerted an antiviral effect on days 1 and 2 characterised by significant (p=<0.05) reductions in viral RNA of 2.2 Log10 copies/ml and 2.6 Log10 copies/ml respectively. An improved effect on viral shedding was observed in animals that received 500mg/kg epeleuton. Treatment significantly reduced viral shedding (measured by viral RNA) on days 1, 2 and 3 by 3.1 Log10 copies/ml, 4.2 Log10 copies/ml and 2.0 Log10 copies/ml respectively. Viral RNA in the lungs and nasal turbinate was determined at day 4 p.c.. A mean titer of 10.5 Log10 CP/g was detected in the lungs of vehicle control hamsters. Treatment with 250mg/kg epeleuton reduced viral RNA in the lungs by 1.1 Log10 CP/g (non-significant). This effect was seen to be dose dependent (Fig. 2G) . When administered at a higher dose, epeleuton produced a significantly improved effect (p = < 0.05) reducing viral RNA in the lungs by 2.9 Log10 CP/g. Epeleuton produced a similar dose-dependent trend in nasal turbinates. Treatment with 250mg/kg reduced viral RNA in the nasal turbinates by 1.1 Log10 CP/g (nonsignificant). An improved significant response (p = < 0.05) was observed following treatment with 500mg/kg epeleuton. Viral RNA was significantly reduced by 2.2 Log10 CP/g compared to vehicle (Fig. 2H ). Challenge with SARS-CoV-2 resulted in a mean weight loss of 6% in the vehicle arm. Epeleuton attenuated SARS-CoV-2 related weight loss in a dose dependent manner (Fig. 2b) . Consistent with the known disease severity in SARS-CoV-2 infected hamsters no other clinical signs were observed in any treatment group. All animals (n = 18) survived the viral challenge until the scheduled time point of autopsy. Upper and lower respiratory tract involvement is the most common manifestation of SARS-CoV-2 infection, resulting in significant morbidity and mortality 19 . In order to assess the effects of epeleuton against the outcomes of SARS-CoV-2 infection both nasal turbinate and lung tissue were harvested and processed for histopathological analysis at day 4 p.c., the peak of lung viral load and replication in the Syrian hamster model. A summary of histological scores is presented in table S3. No lungs showed definite evidence of interfering concurrent infections (e.g., bacteria or fungi), nor was aspiration of foreign material clearly observed. All animals except one (500mg/kg Epeleuton) showed inflammatory changes in the nasal cavity ( Fig. 3a) consisting of infiltrating heterophilic granulocytes, macrophages and lymphocytes. The most severe rhinitis was present in the vehicle arm (score: 2.83) with decreased rhinitis observed in the 250mg/kg (score 2.0), and 500mg/kg (score 1.17) epeleuton groups. Overall, the severity of rhinitis was significantly (p=<0.05) reduced in animals treated with the higher dose of epeleuton compared to vehicle control. Additional inflammatory lesions consisted of rather mild changes of bronchioles but more severe inflammatory changes of the large bronchi (Fig 4d) . Besides single cell necrosis with desquamation into the lumen infiltrations of heterophilic granulocytes and macrophages were present. The most severe inflammation of the lower airways was observed in the vehicle arm (mean score: 2.17) with decreased lower airway inflammation observed in the 250mg/kg epeleuton (mean score: 0.83) and 500mg/kg epeleuton (mean score: 0.33) arms. The dose dependent reduction in severity of inflammation in the lower airways was significant for both doses of epeleuton. Perivascular and peribronchiolar cuffing with infiltration of lymphocytes, macrophages, and less heterophils occurred in all groups to a variable extent (Fig. 4f) . The most severe changes were observed in the vehicle arm (mean score: 1.67) followed by a significant (p = < 0.05) dose dependent reduction in both 250mg/kg epeleuton (mean score: 0.50) and 500mg/kg epeleuton (mean score: 0.17) groups. Recent studies suggest several potential targets for fatty acid binding to SARS-CoV-2 and provide evidence that polyunsaturated fatty acids can exert direct antiviral effects independent of host factors. The identified binding targets include a free fatty acid (FFA) binding pocket on the spike protein (S) 13 The need for an expanded armamentarium for the treatment of COVID-19 is especially evident considering the potential for the development of drug resistance to existing therapies and the emergence of new SARS-CoV-2 variants 9 . Combination therapy utilising drugs with different mechanisms of action may add to the treatment options available and may be more effective than single agents by exploiting potentially additive effects. Instructive precedents include combination approaches for the treatment of human immunodeficiency virus and hepatitis C virus which yielded improved efficacy compared to single agents as well as promising combination approaches for treating MERS-CoV 33, 34, 35. Although the mechanism of action of epeleuton against SARS-CoV-2 requires further characterisation, it is anticipated that epeleuton acts through a distinct and unique mechanism compared to currently available therapeutics such as the nucleoside analogs remdesivir and molnupiravir, the REGN-COV2 monoclonal antibody combination, Paxlovid and corticosteroids. It is noteworthy that following the discovery of the FFA binding pocket on the S protein, in vitro experiments revealed that supplementation of the polyunsaturated fatty acid LA synergizes with remdesivir, suppressing SARS-CoV-2 replication more effectively than with remdesivir alone 13 . Epeleuton is orally administered with a favourable safety and tolerability profile 11 Limited. Hydroxypropyl methyl cellulose (HPMC) (Methocel E4M) was supplied by IMCD UK Ltd. The dose vehicle was prepared as a 0.5% (w/v) aqueous solution and stored in a refrigerator set to maintain a temperature of +2-8°C until use. Ten male Sprague Dawley rats were used in this study. Animals were supplied by Charles River Ltd., Margate UK. Animals were acclimatised to the experimental unit for at least 5 days prior to study commencement. During the pre-trial and on-study periods, animals were group housed in caging appropriate to the species. A standard laboratory diet (SDS RM1 € SQC, batch 2193) and mains quality tap water were available ad libitum throughout the study. Eleven male Sprague Dawley rats (n=5/group) received a once daily oral dose of 500mg/kg Epeleuton or vehicle for 7 days. Animals were observed 15, 30 and 60 minutes following each dose administration. On day 8, 24 hours following the final daily dose (on day 7), animals were humanely sacrificed and samples collected. Approximately 24hrs following completion of the dosing regimen, on Day 8, a terminal blood sample was collected from each animal from the orbital sinus (under anaesthetic). The animals were then humanely sacrificed by CO2 narcosis and the following tissues removed, weighed, snap frozen in liquid nitrogen and stored in a freezer set to maintain a temperature of -80°C until analysis: Lungs (perfused with phosphate buffer saline), heart, brain, eyes, liver, kidney, spleen, colon and skin (shaved). Blood samples were centrifuged (1500g, 10min, +4°C) and the resultant plasma stored in a freezer set to maintain -80°C until analysis. For each batch, calibration samples were freshly prepared in 5% (w/v) Bovine Serum Albumin (BSA) in phosphate buffered saline (PBS) to prevent the potential effect of the 15(S)-HEPE endogenous levels on the assay. The standards, quality control and test samples were prepared, extracted and analysed in batches using research grade methodology detailed in the following sections. Test samples resulting in a determined concentration below the lowest calibration standard were reported as less than the lower limit of quantification (